Replies to post #47517 on Ayala Pharmaceuticals Inc (ADXS)

[DewDiligence]

given all the positive news and preliminary results surrounding neoantigen vaccines, why is there not much excitement about the Advaxis implementation? Is there some perceived disadvantage of their approach, or is the only disadvantage that they have not yet started a phase I trial?

Yes, there will be more investor/analyst interest in the ADXS-NEO program once it starts dosing patients. ADXS' generally poor reputation is also a factor (IMO), as compared to some of the other companies (public and private) who are pursuing neoantigen cancer vaccines.

Are the companies mentioned in this article further ahead in that sense?

Some are. Although not mentioned in the Nature article, ADRO is another neoantigen company ahead of ADXS on timing (#msg-134949543).